Table 1 Patients’ clinicopathological parameters (n = 241)
Variables | Number | Percent (%) |
|---|---|---|
Age (years) | ||
  < 48 | 108 | 44.81 |
  ≥ 48 | 133 | 55.19 |
Body mass index (kg/m2) | ||
  < 24 | 125 | 51.90 |
  ≥ 24 | 116 | 48.10 |
Clinical T stage | ||
 T1 | 26 | 10.79 |
 T2 | 166 | 68.88 |
 T3-T4 | 49 | 20.33 |
Clinical N stage | ||
 N0 | 84 | 34.85 |
 N1–N3 | 157 | 65.15 |
Grade | ||
 Grade1 | 3 | 1.24 |
 Grade2 | 120 | 49.79 |
 Grade3 | 70 | 29.05 |
 UN | 48 | 19.92 |
Phenotype by IHC | ||
 HR-positive | 101 | 41.90 |
 HER-2-positive | 87 | 36.10 |
 Triple-negative | 53 | 22.00 |
Ki67 proliferation index | ||
  ≤ 20 | 69 | 28.63 |
  > 20 | 172 | 71.37 |
Nac regimens | ||
 Anthra based | 39 | 16.18 |
 Tax based | 25 | 10.37 |
 Anthra + Tax based | 177 | 73.44 |
SIRI | ||
  < 0.72 | 63 | 26.14 |
  ≥ 0.72 | 178 | 73.86 |
NLR | ||
  < 1.77 | 28 | 11.62 |
  ≥ 1.77 | 213 | 88.38 |
LMR | ||
  < 5.38 | 201 | 83.40 |
  ≥ 5.38 | 40 | 16.60 |
ALC | ||
  < 1.57 | 132 | 54.77 |
  ≥ 1.57 | 109 | 45.23 |
Response to NAC | ||
 pCR | 48 | 19.92 |
 N-pCR | 193 | 80.08 |